ArticleBMC anesthesiology2026
Anesthetic recovery profiles of intrathecal ropivacaine and bupivacaine in ASA I-II patients undergoing outpatient total hip arthroplasty.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSpinal anesthesia is commonly used in outpatient total hip arthroplasty (THA). Optimizing the duration of sensory and motor blocks is critical for early postoperative recovery.
objectiveThis study aimed to compare the duration of motor block and post-anesthesia care unit (PACU) stay between intrathecal bupivacaine and ropivacaine in patients undergoing outpatient THA.
methodsA total of 220 ASA I-II patients scheduled for outpatient THA were retrospectively analyzed. Of these, 110 patients received 12-14 mg of intrathecal bupivacaine, and 110 patients received 14-16 mg of intrathecal ropivacaine. The primary outcomes were the duration of motor block and the length of PACU stay, and secondary outcomes included time to discharge and postoperative complications.
resultsThe mean (SD) dose of spinal anesthetic was 14.9 (0.7) mg in the ropivacaine group and 12.6 (0.8) mg in the bupivacaine group. Ropivacaine was associated with a significantly shorter duration of motor block (mean difference 44.9 min; 95% CI 33.2-56.6; P < 0.001), PACU stay (median difference 12.3 min; 95% CI 2.1-22.6; P = 0.019), and time to first postoperative void (mean difference 0.6 h; 95% CI 0.1-1.0; P = 0.009). Ropivacaine provided more predictable motor block duration than bupivacaine (P < 0.001), with similar variability in PACU time. No significant between-group differences were observed in discharge time or postoperative complications.
conclusionIntrathecal ropivacaine provides a shorter motor block duration and faster early recovery compared with bupivacaine in outpatient THA, without increasing postoperative complications, but confirmation in a well-designed prospective study is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.